eCancer

Glioblastoma (GBM) is a highly aggressive brain cancer with poor patient outcomes. This study uses a multi-step approach to identify reliable genetic markers for the disease. First, we analysed the GSE4290 dataset, comparing 77 tumour samples to 23 healthy brain controls to identify significantly overexpressed genes. To ensure these findings were not specific to a single study, we validated our results using the GSE147352 dataset.

Olfa Hanaa Aissa, Aicha Rabah, Abdelkader Bousahba, Nawel Nassima Benchiha, Boumediene Elhabachi, Lynda Addou-Klouche Breast cancer is the most frequently diagnosed malignancy and the leading cause of cancer-related death among women. It is a biologically heterogeneous disease resulting from a multifactorial process.

The U.S. Food and Drug Administration (FDA) has approved daraxonrasib, an oral multi-selective RAS(ON) inhibitor, for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or are not candidates for multiagent systemic therapy.

A team of Weill Cornell Medicine investigators has developed a computer model that will help scientists more efficiently develop protein-destroying therapies, a newer type of treatment that is particularly promising for cancer. The study was published in Nature Communications. Most drugs use a small molecule to render disease-causing proteins harmless, but protein-degrader therapies aim to destroy the target protein altogether.

Breast cancer is often classified as either oestrogen receptor-positive (hormone-sensitive) or not. However, a new study from Karolinska Institutet suggests that this simplified classification may overlook important biological differences between patients that could affect treatment decisions. The results are published in The Lancet Regional Health – Europe.

Global cancer burden continues to shift, driven by population ageing, lifestyle changes, and disparities in screening and prevention. A new special issue of Cancer Biology & Medicine brings together works that examine cancer epidemiology from a worldwide perspective—covering ovarian, lung, colorectal, and breast cancers, as well as emerging approaches to multi‑cancer early detection and risk prediction.

In a new study published in Nature Communications, Boston Children’s Hospital researchers have identified a new target responsible for scar formation in the bone marrow of patients with a type of blood cancer known as myelofibrosis. Combining traditional myelofibrosis therapy with drugs that block the scar formation may be a more effective method for treating patients with the disease.

Story-based testing reveals undetected memory difficulties in breast cancer survivors Standard memory tests such as word-pair or list-learning tests used in clinics may fail to detect the real-life memory problems reported by many female breast cancer survivors after chemotherapy.

Results of the NRG Oncology NRG-GU005 clinical study comparing stereotactic body radiation therapy (SBRT) to moderately hypofractionated intensity-modulated radiation therapy (MH-IMRT) for patients with localised intermediate risk prostate cancer indicate that the use of SBRT improved bowel health related quality of life (HRQOL) in this patient population. There was no significant improvement for SBRT seen for the other primary objectives including urinary HRQOL and disease-free survival.